Biocryst Pharmaceuticals' Fodosine(TM) Data To Be Presented At The 2006 American Society of Hematology
BIRMINGHAM, Ala., Dec. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that data related to Fodosine(TM) (forodesine hydrochloride) in the treatment of certain types of leukemias and lymphomas will be presented December 10 at the annual meeting of the American Society of Hematology (ASH) in Orlando, Florida. The data will be presented in poster sessions by leading investigators in the company's ongoing Fodosine(TM) clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website, http://www.hematology.org.
Madeleine Duvic, M.D., Deputy Chair, Dermatology, The University of Texas M.D. Anderson Cancer Center, is scheduled to present updated data from a clinical study of Fodosine(TM) in refractory cutaneous T-cell lymphoma. The poster Dr. Duvic will present is titled, "Oral Forodesine (BCX-1777) is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study."
Richard Furman, M.D., head of CLL and Waldenstrom's Macroglobulinemia program at Weill Medical College of Cornell University in New York, is scheduled to present interim data from the Phase II study of Fodosine(TM) in T-cell leukemia. Dr. Furman will present a poster titled, "Forodesine IV (BCX-1777) is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report)."
Ellen Ritchie, M.D., Assistant Professor of Medicine at Weill Medical College of Cornell University in New York, is scheduled to present interim data from a clinical study of Fodosine(TM) in B-Cell acute lymphoblastic leukemia. Dr. Ritchie will present the poster, "Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia."
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The Company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases, peramivir in seasonal and life- threatening influenza and BCX-4678 in hepatitis C. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208 and is collaborating with Mundipharma Holdings for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. For more information about BioCryst, please visit the Company's web site at http://www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) pursuant to the Special Protocol Assessment letter that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners or governmental agencies for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst, and the risks, uncertainties and factors identified in the documents BioCryst files periodically with the Securities and Exchange Commission, specifically including BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K. These statements reflect our current views with respect to future events and BioCryst has no obligation to update or revise the statements. BioCryst cautions that you should not place undue reliance on these forward-looking statements.
Contact: BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633Photo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, firstname.lastname@example.orgBioCryst Pharmaceuticals, Inc.
CONTACT: Jonathan M. Nugent, V.P. Corporate Communications of BioCrystPharmaceuticals, Inc., +1-205-444-4633